Unibest

Pharmaceutical intermediates

Erlotinib Intermediates

2 pharmaceutical intermediates for Erlotinib. Indication: Pancreatic Neoplasm; Carcinoma, Non-Small-Cell Lung.

Submit a ProjectAll intermediates

About Erlotinib

Originator
Genentech
Indication
Pancreatic Neoplasm; Carcinoma, Non-Small-Cell Lung
Approved Date
12/18/2004

Available intermediates

2 intermediates currently listed for Erlotinib. Request specifications, documentation or a quotation for any item below.

Erlotinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate hydrochloride183322-17-0//
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline183322-18-1//

Other programs under E

Edoxaban tosylate monohydrateElacestrantElagolix SodiumEldecalcitolElinzanetantElobixibatEltrombopagEltrombopag Olamine

Building toward Erlotinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →